Author | D’vorah Graeser, Graeser Associates International

Articles

U.S. Biosimilars Under Threat?

April 27, 2012

Pharmaceutical Executive

Article

While the FDA continues to develop its guidance for U.S. biosimilars, including a one-day public hearing on May 11, 2012, the basic legal underpinnings of biosimilars in the U.S. may be under threat, as the Supreme Court debates the healthcare law, a large chunk of which includes provisions for biosimilars.